Malignant benign hematology

ISTH Academy, Michelle Sholzberg, 273413

Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study

ISTH Academy, Correspondence |Emilie Chalayer, 273414

The effect of stopping phenprocoumon 5 days preoperatively: A retrospective study

ISTH Academy, Correspondence |Marcel van de Ree, 273415

Fondaparinux in heparin‐induced thrombocytopenia: A decade's worth of clinical experience

ISTH Academy, Correspondence |Marc Schindewolf, 273416

Education needs of nurses in thrombosis and hemostasis: An international, mixed‐methods study

ISTH Academy, Correspondence |Patrice Lazure, 273417

Overcoming barriers to integrating direct oral anticoagulants into existing anticoagulation management services

ISTH Academy, Session Speakers, 273418

Circulating endothelial cells as biomarker for cardiovascular diseases

ISTH Academy, Correspondence |Maura Farinacci, 273419

Measurement of tissue factor activity in extracellular vesicles from human plasma samples

ISTH Academy, Nigel mackman, 273420

Circulating microvesicles in snakebite patients with microangiopathy

ISTH Academy, Anoop Enjeti, 273421

ISSUE INFORMATION

ISTH Academy, Session Speakers, 273422

Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay

ISTH Academy, Thomas Mckinnon, 273428

Dietary intake of marine n‐3 polyunsaturated fatty acids and future risk of venous thromboembolism

ISTH Academy, Trond Isaksen, 273429

Barriers to integrating direct oral anticoagulants into anticoagulation clinic care: A mixed‐methods study

ISTH Academy, Geoffrey Barnes, 273430

Polyphosphate in thrombosis, hemostasis, and inflammation

ISTH Academy, Correspondence |James H. Morrissey, 273431

Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?

ISTH Academy, Michael Makris, 273432

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery

ISTH Academy, Flora Peyvandi, 273331

Chronic liver injury drives non‐traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase

ISTH Academy, James Luyendyk, 273332

High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor

ISTH Academy, Suzanne Cannegieter, 273333

Fifty years new

ISTH Academy, Session Speakers, 273334

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays

ISTH Academy, Kenneth Friedman, 273335

Exocytosis of Weibel–Palade bodies: how to unpack a vascular emergency kit

ISTH Academy, Ruben Bierings, 273336

Venous thromboembolism in patients with liver diseases: comment

ISTH Academy, Nicolas Intagliata, 273337

Protease‐activated receptor‐1 impedes prostate and intestinal tumor progression in mice: comment

ISTH Academy, Arnold Spek, 273338

Preventing arteriovenous shunt failure in hemodialysis patients: a population‐based cohort study

ISTH Academy, Hsin‐Hsu Wu, 273339

Corrigendum

ISTH Academy, Session Speakers, 273340

Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura

ISTH Academy, Alice Taylor, 273341

Platelet Shp2 negatively regulates thrombus stability under high shear stress

ISTH Academy, Hu Hu, 273342

Let's cross‐link: diverse functions of the promiscuous cellular transglutaminase factor XIII‐A

ISTH Academy, Nicola Mutch, 273343

A unique phenotype of acquired Glanzmann thrombasthenia due to non‐function‐blocking anti‐αIIbβ3 autoantibodies

ISTH Academy, Hirokazu Kashiwagi, 273344

Erratum

ISTH Academy, Session Speakers, 273345

Suppressing protein Z‐dependent inhibition of factor Xa improves coagulation in hemophilia A

ISTH Academy, sharon smith, 273346

Comparative analysis of marketed factor VIII products: comment

ISTH Academy, Michael Makris, 273347

Comparative analysis of marketed factor VIII products: reply

ISTH Academy, Rachel Weissbrod, 273348

Increased urokinase and consumption of α‐antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay

ISTH Academy, Colin Longstaff, 273349

Novel short peripheral catheter design for prevention of thrombophlebitis

ISTH Academy, Dar Weiss, 273350

Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors

ISTH Academy, Jeffrey Zwicker, 273351

mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors

ISTH Academy, Vladimir Bogdanov, 273352

Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: a blueprint for drugging the microbiota in the treatment of cardiometabolic disease?

ISTH Academy, Max Nieuwdorp, 273353

Issue Information

ISTH Academy, Session Speakers, 273354

Venous thromboembolism in patients with liver diseases: reply

ISTH Academy, Alexandr Balan, 273355

Announcements

ISTH Academy, Session Speakers, 273356

Genetic determinants of activity and antigen levels of contact system factors

ISTH Academy, Bob Siegerink, 273357

Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding

ISTH Academy, Veronica Flood, 273358

Factor XII truncation accelerates activation in solution

ISTH Academy, Coen Maas, 273359

Crosslinked clots formed independently of factor XIII and without fibrinogen‐to‐fibrin conversion – is this a liver‐specific phenomenon?

ISTH Academy, Ton Lisman, 273360

What the neighbors say

ISTH Academy, Session Speakers, 273361

Sulodexide in venous disease

ISTH Academy, Brett J. Carroll, 273362

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro

ISTH Academy, Keiji Nogamimi, 273363

Acquired Thrombocytopenia Course

ISTH Academy, Session Speakers, 234805

Pre-Test

ISTH Academy, Session Speakers, 234804

Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes

ISTH Academy, Frits Rosendaal, 273265

The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply

ISTH Academy, Gualtiero Palareti, 273266

The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: comment

ISTH Academy, Joshua Brown, 273267

The future of bypassing agents for hemophilia with inhibitors in the era of novel agents

ISTH Academy, Amy Shapiro, 273268

Issue Information

ISTH Academy, Session Speakers, 273269

What the neighbors say

ISTH Academy, Session Speakers, 273270

Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism‐specific quality of life

ISTH Academy, Arash Akaberi, 273271

Dimeric FcγR ectodomains detect pathogenic anti‐platelet factor 4–heparin antibodies in heparin‐induced thromobocytopenia

ISTH Academy, P. Mark Hogarth, 273272

Management of venous thromboembolism in patients with cancer

ISTH Academy, Manuel Monreal, 273273

Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease

ISTH Academy, Alan Michelson, 273274

Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population: reply

ISTH Academy, Willem Lijfering, 273275

Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH

ISTH Academy, Rachel Petermann, 273276

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH

ISTH Academy, Michael Makris, 273277

Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer‐associated venous thromboembolism

ISTH Academy, Neil Zakai, 273278

The protease‐activated receptor 4 Ala120Thr variant alters platelet responsiveness to low‐dose thrombin and protease‐activated receptor 4 desensitization, and is blocked by non‐competitive P2Y inhibition

ISTH Academy, Paul F. Bray, 273279

Ultrasound elastography is useful to distinguish acute and chronic deep vein thrombosis

ISTH Academy, Nicola Mumoli, 273280

Genetic regulation of plasma von Willebrand factor levels in health and disease

ISTH Academy, David Lillicrap, 273281

Clinically relevant differences between assays for von Willebrand factor activity

ISTH Academy, Frank Leebeek, 273282

Oxygen saturation or respiratory rate to improve risk stratification in hemodynamically stable patients with acute pulmonary embolism

ISTH Academy, Cecilia Becattini, 273283

Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population: comment

ISTH Academy, Jian‐Hua Zhu, 273284

ISTH News and Updates: Renew Your Membership Today

ISTH Academy, Session Speakers, 273285

Erratum

ISTH Academy, Session Speakers, 273286

The last post

ISTH Academy, Session Speakers, 273287

Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin‐based trigger

ISTH Academy, Hakan Wallen, 273288

The antifibrinolytic and anti‐inflammatory effects of multiple doses of oral tranexamic acid in total knee arthroplasty patients: a randomized controlled trial

ISTH Academy, Wei‐Nan Zeng, 273289

Evaluation of unfractionated heparin versus low‐molecular‐weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer

ISTH Academy, Tyree Kiser, 273290

Safety of D‐dimer testing as a stand‐alone test for the exclusion of deep vein thrombosis as compared with other strategies

ISTH Academy, Synne G. Fronas, 273291

Keeping it clean: clot biofilm to wall out bacterial invasion

ISTH Academy, John W. Weisel, 273292

Hemostatic abnormalities in patients with Ehlers–Danlos syndrome

ISTH Academy, Ida Martinelli, 273293

Module 8 - Prophylaxis of Venous Thrombosis

ISTH Academy, Walter Ageno, 234786

The Evolution in CAT treatment: Digesting New DOACs Studies Data

ISTH Academy, Cihan Ay & Marc Carrier, 223428

Module 4: Drug-Induced Thrombocytopenia

ISTH Academy, Dr. Brian Curtis & Dr. Tamam Bakchoul, 234427

Protease‐activated receptor‐1 impedes prostate and intestinal tumor progression in mice

ISTH Academy, Joseph Palumbo, 273294

Issue Information

ISTH Academy, Session Speakers, 273295

The missing heritability of venous thrombosis: what about factor V Leiden heterogeneity?

ISTH Academy, Pierre-Emmanuel Morange, 273296

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery

ISTH Academy, Ron Mathot, 273297

Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation

ISTH Academy, Christophe Dubois, 273304

The utility of viscoelastic methods in the prevention and treatment of bleeding and hospital‐associated venous thromboembolism in perioperative care: guidance from the SSC of the ISTH

ISTH Academy, Beverley Hunt, 273305

What the neighbors say

ISTH Academy, Session Speakers, 273306

Large‐scale identification of functional microRNA targeting reveals cooperative regulation of the hemostatic system

ISTH Academy, Sven Danckwardt, 273307

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

ISTH Academy, Hermann Eichler, 273308

Enhanced activity of an ADAMTS‐13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke

ISTH Academy, kieron south, 273309

High risk of recurrent venous thrombosis in patients with lower‐leg cast immobilization

ISTH Academy, Banne Nemeth, 273310

Glucose metabolism and metabolic flexibility in blood platelets

ISTH Academy, Khalid M. Naseem, 273311

ADAMTS‐13 activity and ischemic heart disease: a Mendelian randomization study

ISTH Academy, C Mary Schooling, 273312

Repeated assessments of physical activity and risk of incident venous thromboembolism

ISTH Academy, Line H. Evensen, 273320

Hereditary angioedema: the plasma contact system out of control: comment

ISTH Academy, M. Triggiani, 273321

Marc Verstraete (1925–2018)

ISTH Academy, Session Speakers, 273322

Re‐evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology

ISTH Academy, George J. Broze, 273323

Healthcare utilization in chronic thromboembolic pulmonary hypertension after acute pulmonary embolism

ISTH Academy, Yvonne Maria Ende-Verhaar, 273324